Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S158-S178
Open Access | Times Cited: 282

Showing 1-25 of 282 citing articles:

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1206-1222
Open Access | Times Cited: 25
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Yehuda Handelsman, John E. Anderson, George L. Bakris, et al.
Metabolism (2024) Vol. 159, pp. 155931-155931
Open Access | Times Cited: 16
View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences
Guglielmina Froldi
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 478-478
Open Access | Times Cited: 15
Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement
Kariem El‐Boghdadly, Jugdeep Dhesi, Philippa Fabb, et al.
Anaesthesia (2025)
Open Access | Times Cited: 3
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cindy X. Cai, Michelle R. Hribar, Sally L. Baxter, et al.
JAMA Ophthalmology (2025)
Closed Access | Times Cited: 3
Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
J Bernhard, L Galli, Walter S. Speidl, et al.
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Open Access | Times Cited: 2
Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes
Avik Ray, Julie M. Paik, Deborah J. Wexler, et al.
JAMA Internal Medicine (2025)
Closed Access | Times Cited: 2
Ensuring glucagon access for people with diabetes: A case example from community pharmacy
Ashley Meredith, John A. Galdo, Nicole Gorsuch, et al.
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (2025)
Open Access | Times Cited: 1
Use of Cardioprotective Adjuncts in Type 1 Diabetes
Jerry R. Greenfield, R. J. Frampton, Kellie Millard, et al.
Diabetes Therapy (2025)
Open Access | Times Cited: 1
Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes
Juan P. Frías, Alexandria Ratzki‐Leewing, Terry Dex, et al.
Diabetes Obesity and Metabolism (2025)
Open Access | Times Cited: 1
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 12
Current barriers to initiating insulin therapy in individuals with type 2 diabetes
Alba Galdón Sanz-Pastor, Alicia Justel Enríquez, Ana Sánchez Bao, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 9
Diabetes Management in Detention Facilities: A Statement of the American Diabetes Association
Daniel L. Lorber, Nuha A. ElSayed, Raveendhara R. Bannuru, et al.
Diabetes Care (2024) Vol. 47, Iss. 4, pp. 544-555
Open Access | Times Cited: 9
Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
Sungho Bea, Hwa Yeon Ko, Jae Hyun Bae, et al.
Gut (2024), pp. gutjnl-332687
Closed Access | Times Cited: 9
Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
Jia-Chian Hu, Shih‐Chieh Shao, Daniel Hsiang-Te Tsai, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e240946-e240946
Open Access | Times Cited: 8
Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes
Djordje S. Popovic, Dimitrios Patoulias, Paschalis Karakasis, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2497-2500
Closed Access | Times Cited: 7
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Luis A. Rodríguez, Holly Finertie, Romain Neugebauer, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100759-100759
Open Access | Times Cited: 7
Type 2 Diabetes
Allison L. Crawford, Neda Laiteerapong
Annals of Internal Medicine (2024) Vol. 177, Iss. 6, pp. ITC81-ITC96
Closed Access | Times Cited: 7
Metformin beyond type 2 diabetes: Emerging and potential new indications
John R. Petrie
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S3, pp. 31-41
Open Access | Times Cited: 7
Advances in Nanomedicine for Precision Insulin Delivery
Alfredo Caturano, Roberto Nilo, Davide Nilo, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 945-945
Open Access | Times Cited: 7
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes
Huilin Tang, Ying Lü, William T. Donahoo, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 8, pp. 1004-1015
Closed Access | Times Cited: 7
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Kenneth W. Mahaffey, Katherine R. Tuttle, Mustafa Arici, et al.
European Heart Journal (2024)
Open Access | Times Cited: 6
The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review
Liana Iordan, Laura Gaiţă, Romulus Timar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7057-7057
Open Access | Times Cited: 5
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Jung‐Im Shin, Yunwen Xu, Alex R. Chang, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 8, pp. 683-693
Closed Access | Times Cited: 5
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Rohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 10, pp. 904-917
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top